top of page

Medical Cannabis: What Lessons Can Be Learned for the UK?

Cannabis plant in front of a globe


Anne Katrin Schlag


January 15, 2020

Article from Drug Science’s Head of Research – Dr Anne Schlag An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?

Despite the legalization of medical cannabis in the UK in November 2018, patients still lack access to this medicine, with fewer than 10 NHS prescriptions having been written to date.

This paper evaluates the current regulatory regimes of medical cannabis using peer-reviewed and grey literature as well as personal communications. Looking at the six countries that have been at the forefront of prescribing medical cannabis, including case studies of the three largest medical cannabis markets in the EU: Germany, Italy, and the Netherlands. Furthermore, this report examines international examples from Canada, Israel and Australia, all of which have a more successful history of prescribing medical cannabis than the UK. Their legislations are outlined and numbers of medical cannabis prescriptions are provided to give an indication of how successful their regulatory regime has been in providing patient access. Evaluating countries’ medical cannabis regulations allows us to offer implications for lessons to be learned for the development of a successful medical cannabis regime in the UK.

The full text of this report has just become open access and be found here.

Alternatively, an executive summary of this report and the full feature-length report can be downloaded!

For open-access to the full report of this research, see below:

Keep up with developments in drug science

Reading, engaging with, and sharing our publications, papers and commentary gives evidence-based science and policy the audience it needs and deserves.

bottom of page